Urology Times staff

The group discussed wide variation in when and how patients transition from urology to medical oncology.

Clinicians noted that symptoms—bone pain, declining function, anemia, and renal compromise—carry significant weight when choosing therapy.

A major portion of the discussion focused on selecting among ARPIs for use with ADT in the mCSPC setting.

Clinicians noted that the goal of initial therapy is to extend survival while maintaining quality of life, a balance that requires close communication with patients and multidisciplinary coordination

Panelists emphasized that the decision between doublet and triplet therapy must be individualized.

A major focus of the discussion was the growing role of darolutamide (Nubeqa) in the management of mCSPC.

The group agreed that treatment selection for intermediate-risk NMIBC remains a gray area, with decisions often guided more by clinical nuance and patient factors than by strict adherence to risk tables.

Discussion focused on patient selection and clinical scenarios where mitomycin for intravesical solution might be particularly valuable.

The group emphasized that nephron-sparing surgery is now a cornerstone of care for patients with solitary kidneys, borderline renal function, or limited tumor burden.

Attendees highlighted that the standard of care has definitively shifted from ADT monotherapy to combination therapy, leveraging the power of novel androgen receptor pathway inhibitors.

The Oklahoma City discussion underscored that management of mHSPC is no longer defined by a single standard approach.

A focal point of the discussion was the ARANOTE trial, which examined darolutamide plus ADT versus ADT alone in men with metastatic hormone-sensitive prostate cancer who had not received chemotherapy

The discussion opened with how clinicians interpret the term intermediate risk in NMIBC—a category that can encompass multifocal low-grade Ta lesions, solitary tumors larger than 3 cm, or recurrent low-grade disease within 1 year.

The group agreed that the intermediate-risk space is where decision-making is most nuanced.

In this episode, Gregory E. Tasian, MD, MSc, MSCE, Jonathan S. Ellison, MD, and patient partner Annabelle Pleskoff reflect on the origins, design, and key findings of the PKIDS trial.

Panelists discussed how they might incorporate chemoablation into clinical workflows.

Several clinicians observed that patients often fail to understand the distinction between NMIBC and muscle-invasive disease, complicating counseling and referrals.

There was a consensus that soon, combinations like darolutamide plus androgen deprivation are becoming standard options for certain patient populations.

A key theme throughout the discussion was the importance of personalized treatment strategies based on patient-specific factors.

Catch up on exclusive videos you may have missed from the first half of the year.

The conversation touched on risk stratification, which plays a central role in deciding among surgical options.

A major challenge addressed in the Clinical Forum was managing BCG shortages and the implications for patient care.

This Clinical Forum event provided a comprehensive overview of the current landscape in treating NMIBC.

The Clinical Forum underscored the importance of clinical trials and multidisciplinary collaboration in advancing bladder cancer care.

"When we select abiraterone for our patients with mHSPC, there's a choice between generic and branded options," says Paul C. Dato MD.

A recent Urology Times Clinical Forum provided an in-depth overview of current and emerging strategies for managing NMIBC.

A pair of roundtable discussions encompassed a range of topics related to UTUC, including clinical guidelines, treatment considerations, and patient cases.

Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.

Three recent expert-led Clinical Forums explored current challenges and advancements in the management of non–muscle invasive bladder cancer.

In 2 recent case-based roundtable discussions, experts tackled diagnosis and treatment strategy for upper tract urothelial carcinoma.